264888-19-9

Basic information

• Product Name: phosphate
• Synonyms: PHOSPHATE
• CAS NO: 264888-19-9
• Molecular Formula: O4P-3
• Molecular Weight: 94.97
• Mol File: 264888-19-9.mol
• Article Data: 4

Chemical Properties

• Appearance: Clear/Liquid
• Water Solubility: Miscible with water.
• CAS DataBase Reference: phosphate(CAS DataBase Reference)
• NIST Chemistry Reference: phosphate(264888-19-9)
• EPA Substance Registry System: phosphate(264888-19-9)

Safety Data

• Hazardous Substances Data: 264888-19-9(Hazardous Substances Data)

Usage

Description

Excess of phosphate can lead to interactions within the human body with calcium, iron and magnesium, and can lead to diarrhoea and may even be toxic. Phosphate and calcium levels are directly connected, and an excess of phosphate will lead to the removal of calcium from the bones and teeth. This will cause osteoporosis and problems with the health of teeth and gums. Athletes often use phosphate supplementation, but a healthcare specialist should monitor this application. Interactions for phosphate preparations with several over-the-counter and prescription drugs are known. Antacids containing aluminium, calcium and magnesium ions can bind phosphate in the digestive tract and prevent phosphate from being absorbed. This can lead in extreme cases to hypophosphataemia. Potassiumsparing diuretics and potassium supplements in combinationwith phosphate preparations may lead to elevated levels of blood potassium levels (hyperkalaemia). Hyperkalaemia can be a serious life-threatening problem.

Uses

Different sources of media describe the Uses of 264888-19-9 differently. You can refer to the following data:
1. Any salt of phosphoric acid. The salts include disodium phosphate, trisodium phosphate, sodium hexametha, and others. They play a variety of roles such as sequestrants, emulsifiers, solubility enhancers, and buffers in a variety of foods.
2. Phosphate, Ion chromatography standard solution is used as a standard solution in analytical chemistry and in ion chromatography. It is used for calibration of ion chromatography and other analytical techniques.

Veterinary Drugs and Treatments

Phosphate is useful in large volume parenteral fluids to correct or prevent hypophosphatemia when adequate oral phosphorous intake is not possible. Hypophosphatemia may cause hemolytic anemia, thrombocytopenia, neuromuscular and CNS disorders, bone and joint pain, and decompensation in patients with cirrhotic liver disease. There is some controversy whether “a low phos” indicates that treatment is necessary.

Upstream product

• 58-64-0 adenosine 5'-diphosphate 
• 56-65-5 ATP 
• 13674-84-5 tris-(2-chloro, 1-methylethyl)-phosphate 
• 5994-61-6 phosphonomethylimino-di-acetic acid 
• 80-15-9 Cumene hydroperoxide 
• 65814-09-7 imidotrimetaphosphate 
• 56537-13-4 trimetaphosphimate 
• 65814-10-0 diimidotrimetaphosphate 
• 25841-83-2 PN₆OH₉ 
• 22638-09-1 amino-phosphonate 
• 124-43-6 sodium pyrophosphate 

Downstream Products

• 12190-75-9 chloroamine 
• 156-62-7 calcium cyanamide 

Relevant articles and documents

Intrinsic Apyrase-Like Activity of Cerium-Based Metal–Organic Frameworks (MOFs): Dephosphorylation of Adenosine Tri- and Diphosphate

Apyrase is an important family of extracellular enzymes that catalyse the hydrolysis of high-energy phosphate bonds (HEPBs) in ATP and ADP, thereby modulating many physiological processes and driving life activities. Herein, we report an unexpected discovery that cerium-based metal–organic frameworks (Ce-MOFs) of UiO-66(Ce) have intrinsic apyrase-like activity for ATP/ADP-related physiological processes. The abundant CeIII/CeIV couple sites of Ce-MOFs endow them with the ability to selectively catalyse the hydrolysis of HEPBs of ATP and ADP under physiological conditions. Compared to natural enzymes, they could resist extreme pH and temperature, and present a broad range of working conditions. Based on this finding, a significant inhibitory effect on ADP-induced platelet aggregation was observed upon exposing the platelet-rich plasma (PRP) to the biomimetic UiO-66(Ce) films, prefiguring their wide application potentials in medicine and biotechnology.

PROCESS FOR OXIDATION OF N-(PHOSPHONOMETHYL)IMINODIACETIC ACID

An oxidation catalyst is prepared by pyrolyzing a source of iron and a source of nitrogen on a carbon support. Preferably, a noble metal is deposited over the modified support which comprises iron and nitrogen bound to the carbon support. The catalyst is effective for oxidation reactions such as the oxidative cleavage of tertiary amines to produce secondary amines, especially the oxidation of N-(phosphonomethyl)iminodiacetic acid to N-(phosphonomethyl)-glycine.